The COVID-19 pandemic and the emergence of mRNA vaccines have highlighted the importance of nanoparticle formulations – especially lipid-based systems – used for nucleic acid-based APIs. The success of SARS-CoV-2 vaccination programmes across the globe has demonstrated that these nanoparticle-based formulations can be used to produce safe and efficacious medicinal products.